DSFIR DSM-Firmenich AG
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through Perfumery & Beauty; Taste, Texture & Health; and Health, Nutrition & Care segments. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, biomedical materials, and nutrition improvement markets. This segment also offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, postbiotics, probiotics and prebiotics, and active pharmaceutical ingredients; biomedical solutions; and premix, market-ready, and personalized nutrition solutions, as well as expert services in regulatory affairs and nutrition. DSM-Firmenich AG was founded in 1902 and is based in Kaiseraugst, Switzerland.…
Industry Peers
Specialty ChemicalsKey Statistics
About DSM-Firmenich (AMS: DSFIR)
›
DSM-Firmenich (AMS: DSFIR) is listed on Euronext Amsterdam, where its shares trade in EUR. It belongs to the Specialty Chemicals industry, part of the Basic Materials sector, and reports about 20,786 employees.
The shares were at 105.25 EUR on 20 November 2026, up 55.9% over 52 weeks. Its 52-week range is 55.22 EUR to 113.45 EUR: the price is 7.2% below the high and 90.6% above the low.
Its market capitalisation is 25.52B EUR. It pays a dividend yielding 2.39% (it pays out 207% of its earnings), against a median of 1.83% among the dividend payers in that peer group.
DSM-Firmenich reports return on equity of -5.9%, an operating margin of 6.8% and revenue up 0.5% year over year.
Its debt exceeds its cash by 4.46B EUR, a debt-to-equity ratio of 0.29. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 20 analysts cover the stock, with an average rating of Buy; their mean price target of 103.17 EUR is 2.0% below the current price. The next earnings report is expected on 9 February 2027.